Immunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
|
|
- Percival Price
- 6 years ago
- Views:
Transcription
1 01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
2 Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss current immunotherapeutic approaches involving checkpoint inhibitions in the treatment of NSCLC Discuss additional immunotherapeutic approaches being evaluated in the treatment of NSCLC
3 Development of Immunotherapy in the Treatment of Cancer Timeline: The history of cancer immunotherapy 03 Description of immune infiltrates in tumours by Virchow First report of allogeneic bone marrow transplantation Hypothesis of cancer immunosurveillance by Burnet Discovery of MHCIrestricted CD8+ T cell recognition by Zinkernagel and Doherty First study with IL-2 First study with IFNα in melanoma First study with adoptive cell transfer in cancer First study of isolated limb perfusion with TNF in melanoma and sarcoma Rediscovery of the regulatory T cell by Sakaguchi Non-myeloablative chemotherapies and adoptive T cell transfer in melanoma HPV vaccination in VIN FDA approved pembrolizumab and nivolumab for the treatment of melanoma Treatment of cancer with bacterial products by Coley Discovery of crosspresentation by Bevan Key regulators of T-cell response are elucidated FDA approval of sipuleucel-t in prostate cancer and ipilimumab in melanoma Discovery of the dendritic cells by Steinman First study with BCG in bladder cancer (1991, 1994) Characterisation of human TAAs by Rosenberg and Boon ( ,2000) Discovery of the immunological function of TLR FDA approved nivolumab for the treatment of squamous NSCLC Remains an active area of research TAA = Tumour-associated antigen; VIN = Vulvar intraepithelial neoplasia; TLR = Toll-like receptor; BCG = Bacille Calmette-Guerin. 1. Lesterhuis WJ et al. Nat Rev Drug Discov. 2011;10: ;
4 The Concept of Immune Surveillance and Escape 04 Schreiber RD et al. Science. 2011;25:331:
5 Key Regulators of Cytotoxic T Lymphocyte Response 05 Cytotoxic T cell responses are regulated by multiple costimulatory and inhibitory interactions Pardoll DM et al. Nat Rev Cancer. 2012;12:
6 Immune Checkpoint Inhibition in the Treatment of Cancer: MOAs of Anti-CTLA-4 and Anti-PD-1/PD-L1 Agents 06 Ipilimumab Ribas A. N Engl J Med. 2012;366: Nivolumab Pembrolizumab MPDL3280A MEDI4736 Immune checkpoints play an important role in suppressing the body s antitumour response
7 PD-1/PD-L1 Inhibition in the Treatment of NSCLC 07 Phase 3 data: Nivolumab in non-squamous (CheckMate 057) and squamous cell (CheckMate 017) lung cancer Phase 2 data: Atezolizumab in NSCLC (POPLAR trial) Phase 1 data: Pembrolizumab in NSCLC (KEYNOTE 001 trial)
8 CheckMate-057: Phase 3 Trial of Nivolumab vs Docetaxel in Patients With Non-Squamous NSCLC 08 Stage IIIb/IV non-squamous NSCLC Failed one prior platinum-based doublet Prior TKI therapy allowed for known ALK translocation or EGFR mutation Prior maintenance therapy allowed ECOG PS: 0-1 Maintenance therapy included pemetrexed, bevacizumab or erlotinib (not considered a separate line of therapy) Endpoints: Paz-Ares L et al. J Clin Oncol. 2015;33:(suppl; Abstract LBA109). N=582 n=292 n=290 Nivolumab: 3 mg/kg IV Q2Wk Docetaxel: 75 mg/m 2 IV Q3Wk Patients stratified by prior maintenance therapy and line of therapy (2 nd vs 3 rd -line) Primary: OS Secondary: ORR, PFS, correlation between PD-L1 expression and efficacy PD-L1 expression measured using the Dako/BMS automated IHC assay R 1:1 Fully validated with analytical performance having met all pre-determined acceptance criteria for sensitivity, specificity, precision, and robustness Until PD or unacceptable toxicity
9 CheckMate-057: Baseline Characteristics 09 Median age, years (range) 75, % Nivolumab n= (37-84) 7 Docetaxel n= (21-85) 8 Male, % Smoking status, % Current/former smoker Never smoker ECOG PS, % 0 1 Prior maintenance therapy, % No. of prior systemic therapy, % 1 2 EGFR-positive mutation status, % ALK-positive translocation status, % 4 3 Baseline PD-L1 expression, quantifiable (% of evaluable patients) 1% 5% 10% Not quantifiable (% of randomised patients) % (455/582) of randomised patients had quantifiable PD-L1 expression. Baseline expression was well balanced between nivolumab and docetaxel Paz-Ares L et al. J Clin Oncol. 2015;33:(suppl; Abstract LBA109).
10 CheckMate-057: OS (Primary Endpoint) 010 OS (%) yr OS rate = 39% Nivolumab n= Time (months) Docetaxel n=290 mos, mo HR = 0.73 (96% CI: 0.59, 0.89), P= yr OS rate = 51% Nivolumab Docetaxel Number of patients at risk Nivolumab Docetaxel Symbols represent censored observations. CI = confidence interval; HR = hazard ratio. Paz-Ares L et al. J Clin Oncol. 2015;33:(suppl; Abstract LBA109).
11 CheckMate-057: PFS 011 Symbols represent censored observations. Paz-Ares L et al. J Clin Oncol. 2015;33:(suppl; Abstract LBA109).
12 CheckMate-057: OS and PFS Hazard Ratios by Baseline PD-L1 Expression 012 a Interaction P-value from Cox proportional hazard model with treatment, PD-1 expression and treatment by PC-L1 expression interaction. Paz-Ares L et al. J Clin Oncol. 2015;33:(suppl; Abstract LBA109).
13 CheckMate-017: Phase 3 Trial of Nivolumab vs Docetaxel in Squamous NSCLC 013 Second-line, stage IIIb/IV squamous NSCLC Failed one prior platinumbased doublet ECOG PS: 0-1 R 1:1 n=135 n=137 Nivolumab: 3 mg/kg IV Q2Wk Docetaxel: 75 mg/m 2 IV Q3Wk Until PD or unacceptable toxicity Endpoints: Primary: OS Secondary: ORR, PFS, correlation between PD-L1 expression and efficacy Spigel D et al. J Clin Oncol. 2015;33:(suppl; Abstract 8009). N=272 Patients stratified by region and prior paclitaxel use One pre-planned interim analysis for OS The boundary for declaring superiority of OS at the pre-planned interim analysis was P<0.03
14 CheckMate-017: Baseline Characteristics 014 Median age, years (range) 75, % Nivolumab n= (39-85) 8 Docetaxel n= (42-84) 13 Male, % Disease stage, % IIIb IV Performance status, % 0 1 CNS metastasis, % 7 6 Prior paclitaxel, % Current/former smoker, % PD-L1 expression, % 1% 5% 10% Not quantifiable 83% (225/272) of patients had quantifiable PD-L1 expression Spigel D et al. J Clin Oncol. 2015;33:(suppl; Abstract 8009)
15 CheckMate-017: OS (Primary Endpoint) Overall Survival (%) Median OS mo, (95% CI) Nivolumab n= Time (months) Number of patients at risk Nivolumab Docetaxel OS 1-yr OS: 24% 9.2 (7.3, 13.3) HR = 0.59 (95% CI: 0.44, 0.79), P= ) 1-yr OS: 42% Nivolumab Docetaxel Docetaxel n= (5.1, 7.3) 015 CI = confidence interval; HR = hazard ratio. Spigel D et al. J Clin Oncol. 2015;33:(suppl; Abstract 8009).
16 CheckMate-017: PFS (Per Investigator Assessment) 016 Spigel D et al. J Clin Oncol. 2015;33:(suppl; Abstract 8009).
17 CheckMate-017: OS and PFS by PD-L1 Expression 017 Survival benefit with nivolumab is independent of PD- L1 expression level Spigel D et al. J Clin Oncol. 2015;33:(suppl; Abstract 8009).
18 Phase 2 Trial of Atezolizumab vs Docetaxel in 2nd/3rd-line NSCLC (POPLAR) 018 Archival or fresh tissue required for pre-dose testing Spigel AI et al. J Clin Oncol. 2015;33:(suppl; Abstract 8010).
19 POPLAR: Baseline Characteristics 019 Characteristics of patients with NSCLC Atezolizumab (n=144) Docetaxel (n=143) Median age, yr % 39% Male 65% 53% Histology Non-squamous 66% 66% Squamous 34% 34% ECOG score, 0/1 33%/67% 32%/68% No. of prior chemotherapies, 1/2 65%/35% 67%/33% History of tobacco use Never 19% 20% Current 17% 15% Previous 64% 65% Spigel AI et al. J Clin Oncol. 2015;33:(suppl; Abstract 8010).
20 PD-L1 Expression on TC and IC Is a Potential Predictive Biomarker for Atezolizumab in NSCLC 020 Spigel AI et al. J Clin Oncol. 2015;33:(suppl; Abstract 8010).
21 POPLAR: OS (All Patients, ITT) 021 a Stratified HR; data cut-off Jan 30, Spigel AI et al. J Clin Oncol. 2015;33:(suppl; Abstract 8010).
22 POPLAR: PD-L1 Expression and OS 022 Spigel AI et al. J Clin Oncol. 2015;33:(suppl; Abstract 8010).
23 POPLAR: PD-L1 Expression and PFS 023 Spigel AI et al. J Clin Oncol. 2015;33:(suppl; Abstract 8010).
24 Pembrolizumab in the Treatment of NSCLC 024 Garon EB et al. N Engl J Med. 2015;372:
25 Biomarker Analysis 025 Anti-PD-L1 antibody clone 22C3 (Merck) and a prototype IHC assay used to determine PD-L1 status/expression in contemporaneous biopsy samples PD-L1 positivity was defined as membranous staining in 1% of cells (neoplastic and intercalated mononuclear inflammatory cells) Membranous PD-L1 expression 50% selected as the cutoff on the basis of ease of use and ROC (receiveroperating-characteristic) analysis PS = proportion score. Garon EB et al. N Engl J Med. 2015;372: Low High PS: <1% 1%-49% 50%
26 Pembrolizumab in NSCLC: PFS Per Proportional Scores (PS) 026 Garon EB et al. N Engl J Med. 2015;372:
27 Pembrolizumab in NSCLC: OS Per Proportional Scores (PS) 027 Garon EB et al. N Engl J Med. 2015;372:
28 028 Current Considerations With Immunotherapeutic Approaches in the Treatment of NSCLC
29 RECIST Criteria May Not Best Reflect Response Patterns to Immuno-Oncology Agents 029 Tumour Change From Baseline (%) Therapy start 0 Thresholds for response 25 or PD (RECIST) 50 Graphs for illustrative 75 purposes showing 100 responses to ipilimumab in advanced melanoma Time (days) Response after initial increase in tumour volume. Novel and specific to I-O therapy (RECIST or WHO criteria may not be appropriate to assess) Therapy start Tumour Change From Baseline (%) Response in baseline lesions: Typically seen with chemotherapy, but also I-O therapies. Captured by existing RECIST and WHO criteria SD : Slow, steady decline in tumour volume seen with chemotherapy, targeted, and I-O therapies. Captured by existing RECIST and WHO criteria 50 Therapy start Time (days) Time (days) I-O = Immuno-Oncology. Figures adapted from Wolchok JD et al. Clin Cancer Res. 2009;15: ; Hoos A et al. Ann of Oncol. 2012;23(suppl 8):viii47 viii52. Tumour Change From Baseline (%) Time (days) Reduction in tumour burden after appearance of new lesions. Novel and specific to I-O therapy (RECIST or WHO criteria may not be appropriate to assess) Therapy start Total Baseline New lesions 25 Tumour Change From Baseline (%)
30 Is Monotherapy Enough? 030 ORR ranges from 15% to 24.8% for anti-pd-1/pd-l1 monotherapy in previously treated or untreated patients with NSCLC Depends on your expectations!
31 What Is the Right Partner for Combination? 031 Chemotherapy? Atezolizumab + platinum doublet untreated NSCLC: ORR of 67% 1 Nivolumab + platinum doublet shows similar efficacy with nivolumab monotherapy in untreated NSCLC (CheckMate-012) 2 Another checkpoint inhibitor (eg, ipilimumab)? Nivolumab + ipi in 2nd-line NSCLC: 39% ORR 3 Targeted agent? Nivolumab + erlotinib in erlotinib failure patients: 19% ORR 4 Tolerability (discontinuation due to treatment-related AEs)? Nivolumab + platinum doublet: 21% 2 Nivolumab + erlotinib: 19% 4 1. Liu SV et al. J Clin Oncol. 2015;33:(suppl; Abstract 8030). 2. Antonia SJ et al. Multidisciplinary Symposium in Thoracic Oncology Abstract Patnaik A et al. J Clin Oncol. 2015;33:(suppl; Abstract 8011). 4. Rivni NA et al. J Clin Oncol. 2014:32:(suppl; Abstract 8022).
32 Anti-PD-1/PD-L1 in EGFR Mutation+ NSCLC? CheckMate Treatment effect on OS in predefined subgroups Paz-Ares et al. ASCO Abstract LBA109.
33 033 PD-L1 as a Potential Predictive Biomarker?
34 PD-L1 as a Potential Predictive Biomarker? 034 Kerr K. ASCO Discussant.
35 PD-L1 as a Potential Predictive Biomarker? (cont d) Spira et al. ASCO Abstract 8010 POPLAR: Atezolizumab vs docetaxel in prev-rx NSCLC PD-L1 as measured appears predictive of ORR, PFS and OS 035 Kerr K. ASCO Discussant.
36 PD-L1 as a Potential Predictive Biomarker? (cont d) PD-L1 expression on TC and IC is a potential predictive biomarker for atezolizumab in NSCLC 036 Kerr K. ASCO Discussant. TC scored as percentage of tumour cells positive - any intensity IC scored as percentage of tumour area with positive cells - any intensity TC3 or IC3 = TC 50% or IC 10% PD-L1+ TC2/3 or IC2/3 = TC or IC 5% PD-L1+ TC1/2/3 or IC1/2/3 = TC or IC 1% PD-L1+ TC0 and IC0 = TC and IC<1% PD-L1
37 OS and PFS Hazard Ratios by PD-L1 Status (CheckMate017) 037 PD-L1 expression NIVO Patients, n DOC Unstratified HR(95% Cl) OS 1% (0.45, 1.05) <1% (0.37, 0.92) All hazard ratios 5% (0.31, 0.89) <5% (0.47, 1.02) 10% Favour Nivolumab (0.28, 0.89) <10% over Docetaxel (0.48, 1.01) Not quantifiable at baseline (0.19, 0.82) PFS 1% Regardless 63 of (0.44, 1.01) <1% PD-L1 status (0.43, 1.00) 5% (0.32, 0.90) <5% (0.52, 1.08) in squamous cell 10% (0.33, 1.02) <10% carcinoma (0.49, 0.99) Not quantifiable at baseline (0.23, 0.89) Spigel D et al. J Clin Oncol. 2015;33:(suppl; Abstract 8009) NIVO DOC
38 OS and PFS Hazard Ratios by PD-L1 Status (CheckMate057) 038 PD-L1 expression level NIVO n DOC n Unstratified HR (95% Cl) OS HRs 1% (0.43, 0.82) <1% (0.66, 1.24) 5% Favour (0.30, 0.63) <5% Nivolumab (0.77, 1.34) 10% over (0.26, 0.59) <10% (0.76, 1.31) Docetaxel Not quantifiable at baseline (0.61, 1.35) PFS in 1% (0.53, 0.94) <1% PD-L (0.88, 1.61) 5% positive (0.39, 0.76) <5% (1.01, 1.71) 10% Nonsquamous (0.37, 0.75) <10% (0.96, 1.61) Not quantifiable at baseline (0.73, 1.56) cell carcinoma P-value a < NIVO DOC a Interaction P-value from Cox proportional hazard model with treatment, PD-L1 status and treatment by PD-L1 status interaction. Paz-Ares L et al. J Clin Oncol. 2015;33:(suppl; Abstract LBA109).
39 Differences Between Squamous and Non-Squamous Cancers? 039 Kerr K. ASCO Discussant. Biomarker not predictive in Squamous (017) but predictive in non-squamous (057) CheckMate057: Significant improvement in median OS but not median PFS CheckMate017: Significant improvement in median OS and PFS Same drug, same biomarker Current/former smokers CheckMate 017: 92% CheckMate 057: 79.5%; EGFR/ALK in 17.5% Greater mutational load in 017 squamous cell cancers? Immune system and squamous vs glandular epithelia? Does the immune status or immune microenvironment differ between these patients? Immune infiltrates in and around tumours differ Does the mutation burden make a difference? Are immunomodulatory mechanisms different? Are the cut offs correct? Are 1, 5 & 10% too low?
40 PD-L1 as a Potential Predictive Biomarker? (cont d) 040 Data are variable Rule in/rule out Biomarker to predict patient will benefit (and to what degree) Biomarker to predict patient will not benefit 10% is easier than 5% is easier than 1% Assessment of immune cells Relevance of immune cells present? Cytology samples lack architecture Is a biomarker required? Kerr K. ASCO Discussant.
41 PD-L1 as a Potential Predictive Biomarker? (cont d) 041 Is it the correct marker? Does the oncology community trust immunohistochemistry? Are our expectations of a biomarker in this setting reasonable? PD-L1 is not present or absent Expression is biological continuum Cut offs; definitions of positive are artificial Kerr K. ASCO Discussant.
42 PD-L1 as a Potential Predictive Biomarker? (cont d) 042 Is it the correct marker? Does the oncology community trust immunohistochemistry? Are our expectations of a biomarker in this setting reasonable? PD-L1 is not present or absent Expression is biological continuum Cut offs; definitions of positive are artificial Immune Checkpoint inhibition is NOT like inhibiting an addictive oncogene driver Four drugs, four different biomarker tests, all for PD-L1 Kerr K. ASCO Discussant.
43 Other Potential Biomarkers for Response? 043 Other immune checkpoints Immune cells Overall infiltrate Specific cell types Immune gene signatures Mutational burden Global burden Mismatch repair genes (MMR) Microsatellite instability (MSI) Polymerase E (POLE) mutations Smoking
44 044 Immune Checkpoint Inhibition Is an Active Area of Clinical Development in the Treatment of NSCLC
45 Phase 3 Trials With Immunotherapeutic Agents in NSCLC 045 Agent Patients Regimen 1 Endpoint Status Ipilimumab (NCT ) Ipilimumab (NCT ) Nivolumab (NCT ) Nivolumab (NCT ) Nivolumab (NCT ) Stage IV or recurrent SCC Chemo-naive or recurrent stage IV or recurrent NSCLC Stage IIIB-IV NSCLC; failed at least one prior systemic regimen Chemo-naive or recurrent stage IV NSCLC Chemo-naive or recurrent stage IV NSCLC Ipilimumab + CP vs Placebo + CP Nivolumab vs nivolumab + Ipi vs platinum doublet* Nivolumab 3 mg/kg IV until progression vs Nivolumab 3 mg/kg IV 1 year Nivolumab vs platinum doublet Nivo vs nivo + ipi vs platinumdoublet OS OS PFS Grade 3-4 and 5 treatment-related AEs PFS OS PFS Currently recruiting Not yet recruiting Currently recruiting Currently recruiting Not yet recruiting *Squamous: gemcitabine + cisplatin or carboplatin; non-squamous: pemetrexed + cisplatin or carboplatin. CP = carboplatin + paclitaxel. Available at: Accessed July 15, 2015.
46 Phase 3 Trials With Immunotherapeutic Agents in NSCLC 046 Agent Patients Regimen 1 Endpoint Status Pembrolizumab (NCT ) Untreated stage IV strong PD-L1- expressing NSCLC Pembro vs PC vs Pem + C vs Pem + Cis vs Gem + Cis vs Gem + C PFS Currently recruiting Pembrolizumab (NCT ) MEDI4736 (NCT ) Chemo-naive PD-L1+ NSCLC Chemo-naive advanced or metastatic NSCLC Pembro vs Standard of care platinum doublet MEDI vs MEDI + Treme vs platinum doublet OS PFS Currently recruiting Not yet recruiting MEDI4736 (NCT ) Stage IIIb/IV NSCLC failed 2 prior therapies PD-L1+: MEDI vs SOC PD-L1-: MEDI vs SOC vs MEDI + Treme vs SOC PFS Currently recruiting SOC = standard-of-care; C = carboplatin. Available at: Accessed July 15, 2015.
47 Phase 3 Trials With Immunotherapeutic Agents in NSCLC 047 Agent Patients Regimen 1 Endpoint Status MEDI4736 (NCT ) MEDI4736 (NCT ) MEDI4736 (NCT ) Completely resected NSCLC T790M+NSCLC failed prior EGFR TKI Stage III NSCLC not progressed following definitive platinum-based concurrent chemoradiation MEDI vs placebo DFS Currently recruiting MEDI + AZD9291 vs AZD9291 MEDI vs placebo PFS OS PFS Not yet recruiting Currently recruiting Available at: Accessed July 15, 2015.
48 Phase 3 Trials With Immunotherapeutic Agents in NSCLC 048 Agent Patients Regimen 1 Endpoint Status Atezolizumab (NCT ) Atezolizumab (NCT ) Atezolizumab (NCT ) Atezolizumab (NCT ) Atezolizumab (NCT ) Atezolizumab (NCT ) Chemo-naive, stage IV squamous NSCLC Chemo-naive or recurrent stage IV or recurrent NSCLC Chemo-naive or recurrent stage IV or recurrent NSCLC Chemo-naive stage IV SCC Chemo-naive stage IV NSCLC Completely resected stage IB- IIIA NSCLC MPDL vs Gem + Cis vs Gem + C MPDL vs C or cis + pem MPDL + nab-cp vs nab-cp MPDL + CP or MPDL + nab-cp vs nab-cp MPDL + CP vs MPDL + CP + bev vs CP + bev PFS PFS PFS PFS PFS Currently recruiting Currently recruiting Currently recruiting Currently recruiting Currently recruiting MPDL vs BSC DFS Currently recruiting CP = carboplatin + paclitaxel; nab-cp = carboplatin + nab-paclitaxel; C = carboplatin. Available at: Accessed July 15, 2015.
49 049 Vaccines in the Treatment of NSCLC
50 MOA of Cancer Vaccines 050 Tumour cells Adapted from Drakes CG et al. Nat Rev Clin Oncol. 2014;11:24-37.
51 MAGE-A3 and Adjuvant Therapy 051 MAGE-A3 is an antigen that is expressed almost exclusively on the surface of tumour cells, including NSCLC % of NSCLC expresses MAGE-A3 Expression is associated with poor prognosis Phase 2 trial in stage IB-II completely resected NSCLC: MAGE-A3 vaccine vs SOC 2 DFS: HR 0.76 (95% CI: ) OS: HR 0.81 (95% CI: ) MAGRIT trial: Phase 3 trial of MAGE-A3 cancer vaccines vs placebo in stage IB-IIIA completed resected NSCLC (N=2278) 3 2:1 randomisation Primary endpoint: DFS Study was discontinued by GSK due to failure to meet its primary endpoint 1. Massarelli E et al. Transl Lung Cancer Res. 2014;3:53-63; 2. Vansteenkiste J et al. J Clin Oncol. 2013;31: ; 3. GSK website. Accessed August 4, 2015.
52 Select Ongoing Phase 3 Trials With Vaccine in NSCLC 052 Agent Patients Regimen 1 Endpoint Status EGF cancer vaccine (NCT ) Untreated EGFR WT NSCLC EGF cancer vaccine vs BSC OS Currently recruiting Tergenpumatucel-L (NCT ) Progressive or relapsed NSCLC Tergenp vs docetaxel OS Currently recruiting GV1001 (NCT ) Inoperable stage III postchemoradiation therapy GV1001 vs BSC OS Not yet recruiting Racotumomab (NCT ) Previously treated stage IIIA-B, IV NSCLC Racotumomab vs BSC OS Currently recruiting TG4010 (NCT ) Untreated stage IV NSCLC TG chemo vs placebo + chemo PFS (Phase 2) OS (Phase 3) Currently recruiting BSC = best supportive care. Available at: Accessed July 15, 2015.
53 BI *: Therapeutic mrna-based Vaccine 053 A novel investigational therapeutic mrna-based vaccine developed in collaboration with CureVac Mobilises the patient s own immune system to fight the tumour with a specific immune response Clinical investigation is underway in lung cancer settings Source: *This is an investigational compound and has not yet been approved. Its safety and efficacy have not yet been fully established. mrna = messenger ribonucleic acid. Source: Boehringer Ingelheim (data on file).
54 BI : Current Clinical Development st -line EGFR m+ combo with afatinib Monotherapy in locally advanced disease after chemoradiation
55 Summary/Conclusion 055 Recent advances in molecular biology have revived and validated immunotherapeutic approaches for the treatment of cancer Anti-PD-L1mAb has significantly improved survival in patients with advanced or metastatic NSCLC However, there are still a number of issues associated with anti-pd-1/pd-l1 therapy, and it continues to be an active area of research and development Additional therapeutic approaches under clinical development include cancer vaccination
Patient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationUpdates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer
Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationINMUNOTERAPIA II. Dra. Virginia Calvo
INMUNOTERAPIA II Dra. Virginia Calvo LBA53. IMpower130. Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with o without atezolizumab
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationPD-(L)1 Inhibitors and CTLA-4 Inhibitors: Rationale for Combinations and Recent Data in Non-Small Cell Lung Cancer
PD-(L)1 Inhibitors and CTLA-4 Inhibitors: Rationale for Combinations and Recent Data in Non-Small Cell Lung Cancer Rebecca S. Heist, MD, MPH Abstract The recent success of PD-1 and PD-L1 inhibitors in
More informationImmunotherapy in lung cancer. Saurabh maji
Immunotherapy in lung cancer Saurabh maji Worldwide, lung cancer is the most common cause of cancerrelated deaths Small cell lung cancer (SCLC) presents with widespread disease at the time of diagnosis,
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationUpdates in Lung Cancer. J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationImmunotherapy in Non-Small Cell Lung Cancer
Immunotherapy in Non-Small Cell Lung Cancer Renato G. Martins Stephen H. Petersdorf Endowed Chair in Cancer Care Associate Medical Director, Solid Tumor Adult Oncology, Seattle Cancer Care Alliance Professor,
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationUpdates in Lung Cancer
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More information